Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Dalmelitinib is a selective, orally active c-Met kinase inhibitor (IC50: 2.9 nM) that binds the ATP-binding region of c-Met. Dalmelitinib induces phosphorylation of MET and partially or completely inhibits phosphorylation of AKT and ERK. dalmelitinib exhibits a potent inhibitory effect on the proliferation of cancer cells (c-Met oncogene amplification) and can be used in cancer research (e.g. non-small cell lung cancer).
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 6-8 weeks | $ 2,140.00 | |
50 mg | 6-8 weeks | $ 2,785.00 | |
100 mg | 6-8 weeks | $ 3,520.00 |
Description | Dalmelitinib is a selective, orally active c-Met kinase inhibitor (IC50: 2.9 nM) that binds the ATP-binding region of c-Met. Dalmelitinib induces phosphorylation of MET and partially or completely inhibits phosphorylation of AKT and ERK. dalmelitinib exhibits a potent inhibitory effect on the proliferation of cancer cells (c-Met oncogene amplification) and can be used in cancer research (e.g. non-small cell lung cancer). |
Molecular Weight | 461.47 |
Formula | C22H16FN7O2S |
CAS No. | 1637658-98-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Dalmelitinib 1637658-98-0 inhibitor inhibit